BreezeBio
This role supports the development of genetic medicines using GenEdit’s hydrophilic nanoparticle (HNP) platform within the product and process development team. The position is based full-time in wet labs, focusing on nanoparticle formulation activities and analytical method development. The hire will work closely with scientists and technicians to generate high-quality data and contribute to process development for next-generation gene therapies and nanomedicines.
Headquarters
Brisbane, California, United States
Company Size
11-50 employees
Founded
2016
BreezeBio (formerly GenEdit) is a biotechnology company focused on precision delivery of genetic medicines to treat autoimmune diseases and oncology. Powered by its NanoGalaxy® programmable nanoparticle delivery platform, BreezeBio targets specific immune cells to restore immune balance and achieve durable cures, with a lead program (BRZ-101) in Type 1 Diabetes. The company advances an internal pipeline of immune-modulating therapies and collaborates with biopharma partners including Genentech and Sarepta Therapeutics.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BreezeBio.
BreezeBio didn’t post a salary, so this is our estimate from similar listings.
Contract SRA / Scientist, Lipid Nanoparticle (LNP) Discovery
Addition Therapeutics
Senior Scientist, Discovery Sciences & Technologies
Gilead Sciences
Scientist I / II, tLNP Process Development
AbbVie
Lipid Nanoparticle & mRNA Synthesis Intern
Sartorius
Scientist, mRNA Formulation
GSK plc
LNP Lab Technician
GenScript